ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
MS_COVID_Saikosaponin.pdf (14.14 MB)

Molecular Docking study of Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein with Saikosaponin, a Triterpenoid Natural Product

preprint
submitted on 26.03.2020 and posted on 26.03.2020 by Tamal Goswami, Bhaskar Bagchi
The appearance of SARS-CoV-2 has resulted ~19000 deaths and ~423000 infections worldwide as of March 24, 2020. Coronavirus spike (S) glycoproteins hooks on target cells and binds to the angiotensin-converting enzyme 2 (ACE2) receptor. Recent researches speculated that residues 331 to 524 of the S glycoprotein of the receptor binding domain (RDB) of the spike is the most crucial target and this side was very important for computational docking. In the present study we have considered a series of saikosaponins and molecular docking was performed. Most of the docked molecules bind favorably to the RDB region of the spike glycoprotein and among them Saikosaponin B4 is the best inhibitor.

History

Email Address of Submitting Author

tamaltgoswami@gmail.com

Institution

Raiganj University, Raiganj, Uttar Dinajpur - 733134, India

Country

India

ORCID For Submitting Author

0000-0003-1628-3204

Declaration of Conflict of Interest

The authors declare no conflict of interest.

Exports